NEW YORK, December 20, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Santarus, Inc. (NASDAQ: SNTS), Hologic Inc. (NASDAQ: HOLX), Brookdale Senior Living Inc. (NYSE: BKD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), and Biodel Inc. (NASDAQ: BIOD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Santarus, Inc. Research Report
On December 17, 2013, Santarus, Inc. (Santarus) stock closed at $31.94, and remained flat as compared to the previous day's closing. The Company's stock went down 0.03% over the past three trading days, compared to the Dow Jones Industrial Average which modestly went up by 0.86% during the same trading period. The Full Research Report on Santarus, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Hologic Inc. Research Report
On December 9, 2013, Hologic Inc. (Hologic) announced the appointment of Stephen P. MacMillan as the Company's President and CEO, and a member of the Board of Directors. David R. LaVance, Jr., Chairman of the Board. "The Board unanimously concluded that his track record of delivering strong financial results and creating shareholder value makes him the ideal chief executive officer for Hologic. During his tenure, Steve led Stryker Corporation to strong operating performance, including nearly tripling revenue, and delivered stock price appreciation that significantly outperformed the S&P 500 index. Hologic has made progress in reviewing the strategy, leadership and cost structure of each of its businesses, and the Board is confident that under Steve's leadership the Company can leverage its strong product platforms to drive value for shareholders and other key stakeholders." The Full Research Report on Hologic Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Brookdale Senior Living Inc. Research Report
On December 17, 2013, Brookdale Senior Living Inc. (Brookdale) stock closed at $26.95, flat as compared to the previous day's closing price. The Company's stock went up 0.37% over the past three trading days, compared to the Dow Jones Industrial Average which modestly went up by 0.86% during the same trading period. The Full Research Report on Brookdale Senior Living Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Idenix Pharmaceuticals Inc. Research Report
On December 2, 2013, Idenix Pharmaceuticals Inc. (Idenix) reported that it has initiated patient enrollment in the phase II HELIX-2 clinical trial, which will evaluate an all-oral, direct-acting antiviral (DAA) HCV combination regimen of samatasvir, Idenix's once-daily pan-genotypic NS5A inhibitor, simeprevir, a once-daily NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB, and TMC647055, a once-daily NS5B non-nucleoside polymerase inhibitor boosted with low-dose ritonavir developed by Janssen. "We are pleased with the continuing progress of our clinical program for samatasvir, which will provide additional important information on the use of this promising compound as part of all-oral HCV combination regimens," said Doug Mayers, M.D., Chief Medical Officer of Idenix. "With the advancement of the samatasvir program as well as that of our novel nucleotide prodrug inhibitor, IDX21437, we anticipate initiating the evaluation of our own HCV combination regimen in 2014." The Full Research Report on Idenix Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Biodel Inc. Research Report
On December 17, 2013, Biodel Inc. (Biodel) announced that it has entered a long-term supply agreement with Becton, Dickinson and Company (BD) for worldwide exclusive rights to the novel and proprietary BD Uniject SCF™ Disposable Auto-Disable Injection System for the delivery of liquid glucagon to treat severe hypoglycemia. Dr. Errol De Souza, President and CEO, Biodel, stated, "We are pleased to achieve another important milestone in our endeavor to redefine the glucose rescue treatment standard. Adding the BD Uniject SCF™ Disposable Auto-Disable Injection System to our existing pipeline of adult and pediatric auto-reconstitution devices will enable us to offer a portfolio of devices to address and expand the underserved glucagon rescue treatment market by replacing antiquated, difficult, and cumbersome multi-part kits with simple, convenient, portable therapies that are close at hand when most urgently needed." The Full Research Report on Biodel Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner